Patents Assigned to Hoechst Japan Limited
-
Patent number: 5541036Abstract: A negative photoresist composition comprising:(A) a compound represented by the following formula (I): ##STR1## wherein R.sup.1 and R.sup.2 which are different from each other represent a hydrogen atom or a group represented by the following formula (II): ##STR2## (B) an alkoxymethylated melamine, and (C) a novolak resin.The photoresist composition has resolution below submicron, and can form resist patterns with an ideal rectangular profile.Type: GrantFiled: April 16, 1993Date of Patent: July 30, 1996Assignee: Hoechst Japan LimitedInventors: Akihiko Igawa, Masato Nishikawa, Georg Pawlowski, Ralph Dammel
-
Patent number: 5525453Abstract: A novel positive-working radiation-sensitive mixture having a high sensitivity to radiation in a short-wavelength UV region is provided which can be developed in an aqueous alkaline solution, has a stable acid latent image and is used for the production of a semiconductor. The mixture comprises, as indispensable components, a) a binder insoluble in water but soluble in an aqueous alkaline solution, b) a compound having at least one bond cleavable with an acid, c) a compound capable of producing an acid upon radiation, and d.sub.1) a basic ammonium compound or d.sub.2) a basic sulfonium compound.Type: GrantFiled: February 15, 1994Date of Patent: June 11, 1996Assignee: Hoechst Japan LimitedInventors: Klaus J. Przybilla, Takanori Kudo, Seiya Masuda, Yoshiaki Kinoshita, Natumi Suehiro, Munirathna Padmanaban, Hiroshi Okazaki, Hajime Endo, Ralph Dammel, Georg Pawlowski
-
Patent number: 5525618Abstract: Treatment of osteopathic comprising administering as an active ingredient a compound represented by the following formula (I), (II) or (III): ##STR1##Type: GrantFiled: April 1, 1994Date of Patent: June 11, 1996Assignee: Hoechst Japan LimitedInventors: Koichi Shudo, Tatsuo Sugioka, Mizuho Inazu, Hideyuki Tanaka, Tsutomu Inoue, Kazuyuki Kitamura
-
Patent number: 5496823Abstract: Pharmaceutical compositions for the improvement of dysuria comprising a pharmaceutical carrier and a therapeutically effective amount of a xanthine derivative represented by the general formula I ##STR1## wherein R.sub.1 denotes a group of the formula R.sub.4 -CO- or R.sub.5 R.sub.6 (OH)C- or a carboxyl group, wherein R.sub.4 and R.sub.5 independently denote an alkyl group having 1-3 carbon atoms, and R.sub.6 denotes a hydrogen atom or an alkyl group having 1-3 carbon atoms, R.sub.2 denotes a hydrogen atom, an alkyl group having 1-5 carbon atoms or an alkyloxy group having 1-5 carbon atoms, R.sub.3 denotes an alkyl group having 1-3 carbon atoms and n denotes 1-6 or a pharmaceutically acceptable acid addition salt thereof.They are active in prolonging urination intervals and increasing urination threshold pressure with almost no influence upon constrictive force of the bladder. Thus, they are effective in treatment and prevention of dysuria such as pollakiuria and incontinence of urine.Type: GrantFiled: August 9, 1994Date of Patent: March 5, 1996Assignee: Hoechst Japan LimitedInventors: Yuko Morioka, Mitsuru Takano
-
Patent number: 5494802Abstract: An animal tissue antigen for osteoporotic patients that reacts with antibody in a serum of human osteoporotic patients, but does not react with that in normal human serum. Preferably, a specific antigen for osteoporotic patients in rat or mouse epithelium of tongue mucous membrane, epithelium of tracheal mucous membrane, upper lip epidermis or follicular epithelium containing upper lip hair shafts, or a specific antigen for osteoporotic patients contained in cultured cells of a human squamous cell tongue carcinoma cell lines such as SCC-9 and fibroblast cell lines such as MRC-5. Osteoporosis can be both specifically and easily diagnosed by bringing the above-mentioned antigen in contact with a serum of a subject and then testing for the presence of an antigen-antibody reaction.Type: GrantFiled: March 17, 1993Date of Patent: February 27, 1996Assignee: Hoechst Japan LimitedInventors: Hiroshi Watanabe, Mikio Akita, Kohsei Gotoh, Kazuyuki Kitamura
-
Patent number: 5460951Abstract: A bone-related carboxypeptidase-like protein named OSF-5 which is obtained from bone tissue of a mammal including mouse or human, and a process for its production. This protein is a novel naturally occurring mammal protein which belongs to a group of carboxypeptidase molecules.OSF-5 acts as an adhesion molecule or a growth factor which takes part in the process of osteogenesis at the site of bone induction. OSF-5 can be used as an agent for treating bone metabolic diseases, and its high organ specificity for bones enables its use as a diagnostic reagent for bone metabolic diseases.Type: GrantFiled: August 26, 1993Date of Patent: October 24, 1995Assignee: Hoechst Japan LimitedInventors: Shinji Kawai, Sunao Takeshita, Makoto Okazaki, Egon Amann
-
Patent number: 5441945Abstract: The heterocyclic iminobismethylenebisphosphonic acid derivatives of the general formula (I) ##STR1## wherein n is an integer of 0-5 and the group of the formula ##STR2## represents a 4-7 membered monocyclic or 7-11 membered condensed heterocyclic ring group which may be substituted by a halogen atom or a lower alkyl group and contains 1-2 nitrogen atoms their esters and salts thereof are described. The said compounds are useful as a bone resorption inhibitor, a dental calculus formation inhibitory agent or a polyvalent metal ion complex salt forming agent.Type: GrantFiled: April 13, 1994Date of Patent: August 15, 1995Assignee: Hoechst Japan LimitedInventor: Katsuhiro Yoshikawa
-
Patent number: 5428181Abstract: A compound represented by the general formula: ##STR1## wherein A-O-denotes a residue of a compound having an estrogenic activity; R.sub.1 denotes H or a C.sub.1 -C.sub.6 alkyl group; X denotes a single bond, a C.sub.1 -C.sub.10 alkylene group or a group of the formula ##STR2## wherein R.sub.2 denotes H or a C.sub.1 -C.sub.5 alkyl group; Z denotes a nitro group or a halogen; n is an integer of 3 to 12; k is an integer of 1 to 5; L is an integer of 0 to 5; and q is an integer of 1 to 3,and physiologically acceptable salts thereof are disclosed.The compounds have a high affinity to bone tissues, and the compounds per se and metabolites thereof show significant therapeutic effect on bone diseases such as osteoporosis, rheumatoid arthritis and osteoarthritis.Type: GrantFiled: December 24, 1992Date of Patent: June 27, 1995Assignee: Hoechst Japan LimitedInventors: Tatsuo Sugioka, Mizuho Inazu
-
Patent number: 5416105Abstract: A pharmaceutical composition containing as an active ingredient glimepiride. The composition is used for preventing or treating arteriosclerosis with no influence on lipid metabolism and no increase in plasma insulin level.Type: GrantFiled: December 23, 1993Date of Patent: May 16, 1995Assignee: Hoechst Japan LimitedInventors: Yusuke Satoh, Toshifumi Inami
-
Patent number: 5385890Abstract: An antithrombin III is described comprising a lyophilized powder of antithrombin III and a polyoxyethylene glycol sorbitan alkyl ester as well as a kit composed of a container wherein a lyophilized powder of antithrombin III is placed and a solvent for the powder, characterized in that a polyoxyethylene glycol sorbitan alkyl ester is added to either or both of the powder and the solvent. The preparation has a high solubility in water by retaining its activity.Type: GrantFiled: September 30, 1993Date of Patent: January 31, 1995Assignee: Hoechst Japan LimitedInventors: Toshinobu Aoyama, Keizo Hirahara
-
Patent number: 5378687Abstract: Use of human blood coagulation factor XIII for the treatment of ulceration colitisThe use of human blood coagulation factor XIII for the treatment of ulcerative colitis is demonstrated in 4 representative cases. Treatment with factor XIII leads to rapid and total disappearence of the chief symptoms realizing transition to the remission stage.Type: GrantFiled: May 13, 1993Date of Patent: January 3, 1995Assignee: Hoechst Japan LimitedInventors: Mikio Urabe, Satoshi Tanaka, Kenichiro Tsumura
-
Patent number: 5331093Abstract: The invention relates to a monoclonal antibody PC47H specifically recognizing fucosylceramide derived from a ceramide-mono-glycoside fraction of neutral glycolipid extracted and purified from human cancer tissues and having properties such as belonging to IgM and showing reactivity to neither of normal peripheral blood lymphocyte, normal erythrocyte, normal fibroblast nor cell lines derived from leukemia, hepatoma, breast cancer and neuroblastoma but to cell lines derived from lung cancer, stomach cancer, colon cancer and pancreas cancer; a hybridoma having ability to produce the aforementioned monoclonal antibody; a method for manufacturing the aforementioned monoclonal antibody which comprises immunizing an animal with a neutral glycolipid fraction extracted from human pancreas cancer, fusing animal cells with myeloma cells to generate hybridomas, cloning the hybridomas, selecting clones which produce monoclonal antibodies which specifically recognize fucosylceramide and then using the clones to manufactureType: GrantFiled: May 27, 1992Date of Patent: July 19, 1994Assignee: Hoechst Japan LimitedInventors: Hideki Ishihara, Hiroshi Hattori, Kenichi Ono
-
Patent number: 5317029Abstract: Pharmaceutical compositions for the inhibition of bone resorption comprising a pharmaceutical carrier and a therapeutically effective amount of a benzopyran derivative represented by the general formula (I) ##STR1## wherein the broken-lined bond denotes an optional double bond, R.sub.1 denotes a hydrogen atom or a hydroxyl group, R.sub.2 denotes a cyano group, a phenylsulfonyl group or a halogen-substituted methoxyl group, and R.sub.3 denotes a group having the formula ##STR2## Since they inhibit bone resorption, they are useful for the treatment and prevention of diseases associated with bone metabolism.Type: GrantFiled: December 14, 1992Date of Patent: May 31, 1994Assignee: Hoechst Japan LimitedInventors: Mizuho Inazu, Ryoichi Satoh, Tsutomu Inoue, Hiroshi Kitagawa, Masakazu Katoh, Heinrich Englert, Denis Carniato, Hans-Jochen Lang
-
Patent number: 5245052Abstract: A process for the manufacture of a 6-acyl-7-deacetylforskolin derivative represented by formula (I) ##STR1## by reacting a 7-acyl-7-deacetylforskolin derivative represented by formula (II) ##STR2## with a strong base in an aprotic solvent.Type: GrantFiled: July 19, 1991Date of Patent: September 14, 1993Assignees: Nippon Kayaku Co. Ltd., Hoechst Japan LimitedInventors: Tochiro Tatee, Tatsuo Sugioka
-
Patent number: 5232841Abstract: Disclosed is a DNA comprising a mucleotide sequence coding for the signal peptide of Bacillus brevis substantially represented by the sequence (I): ##STR1##Type: GrantFiled: May 9, 1991Date of Patent: August 3, 1993Assignee: Hoechst Japan LimitedInventors: Tamotsu Hashimoto, Atsushi Tsujimura, Shigezo Udaka
-
Patent number: 5164373Abstract: An agent for the therapy of diabetic gangrene is described containing blood coagulation factor XIII as the active ingredient.Type: GrantFiled: February 15, 1991Date of Patent: November 17, 1992Assignee: Hoechst Japan LimitedInventors: Masahiko Shikano, Satoshi Tanaka, Masao Ikdea, Hiroshi Nin
-
Patent number: 5114916Abstract: Human blood coagulation factor XIII allows the prevention of intraventricular hemorrhage when administered to premature infants, preferably by intravenous injections.Type: GrantFiled: February 14, 1990Date of Patent: May 19, 1992Assignee: Hoechst Japan LimitedInventors: Akira Shirahata, Minoru Uchida, Satoshi Tanaka, Kenichiro Tsumura
-
Patent number: 5109003Abstract: Therapeutic agents for the treatment of peptic ulcer disease, containing as active ingredient, at least one compound of the general formula I ##STR1## wherein one of R.sup.1 and R.sup.3 is ##STR2## (wherein m is 1-5, R.sup.4 represents a (C.sub.1 -C.sub.4)alkyl group); the other one of R.sup.1 and R.sup.3 is hydrogen, (C.sub.3 -C.sub.6)alkenyl or (C.sub.1 -C.sub.8)alkyl which can be substituted with up to 2 hydroxyl groups or a (C.sub.1 -C.sub.4)alkoxy group; and R.sup.2 is (C.sub.1 -C.sub.4)alkyl.Type: GrantFiled: August 14, 1990Date of Patent: April 28, 1992Assignee: Hoechst Japan LimitedInventors: Toshizo Tanaka, Shoryo Hayashi, Yuko Morioka, Ulrich Gebert
-
Patent number: 5084273Abstract: An anticoagulant containing as active ingredients protein C or activated protein C and heparin has a high anticoagulant activity which cannot be obtained with activated protein C or heparin alone. The activity of the anticoagulant is further increased by addition of AT III.Type: GrantFiled: December 21, 1990Date of Patent: January 28, 1992Assignee: Hoechst Japan LimitedInventor: Keizo Hirahara
-
Patent number: 5082845Abstract: Therapeutic agents for the treatment of peptic ulcer disease, containing as active ingredient, at least one compound of the general formula ##STR1## wherein R.sup.1 and R.sup.3 are the same or different and are each (C.sub.1 -C.sub.8)alkyl, ##STR2## R.sup.2 is (C.sub.1 -C.sub.4)alkyl; R.sup.4 and R.sup.5 are the same or different and are each hydrogen or (C.sub.1 -C.sub.2)alkyl; R.sup.6 is (C.sub.1 -C.sub.2)alkyl; and m, n and p are the same or different and are each 1, 2, 3, 4, 5 or 6; with the proviso that one of the groups R.sup.1 and R.sup.3 is ##STR3## or that R.sup.3 represents ##STR4## Some of the compounds of formula I are novel.Type: GrantFiled: February 17, 1989Date of Patent: January 21, 1992Assignee: Hoechst Japan LimitedInventors: Erhard Wolf, Ulrich Gebert, Harald Furrer, Toshizo Tanaka, Masao Sakurai, Masayoshi Goto